Group 1 - The article discusses the author's long position in shares of BMY, BAYRY, and BASFY, indicating a positive outlook on these companies [1] - It emphasizes the importance of conducting due diligence and research before making any investment decisions, highlighting the risks associated with short-term trading and options trading [2] - The article clarifies that past performance is not indicative of future results and that no specific investment recommendations are provided [3]

KEY TAKEAWAYSBayer shares are falling 11% in German trading after the pharmaceuticals and crop science conglomerate reduced its full-year earnings target amid a tough agricultural market.The Monsanto parent said it now expects 2024 EBITDA before special items of between 10.4 billion euros ($11.05 billion) and 10.7 billion euros ($11.36 billion), down from its previous range of between 10.7 billion euros and 11.3 billion euros.Agricultural companies, including Archer Daniels Midland, have been hit by lower g ...

Bayer (BAYRY) announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency ("EMA") for its pipeline candidate elinzanetant. The MAA is seeking approval of the candidate for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or adjuvant endocrine therapy. Image Source: Zacks Investment Research Year to date, shares of Bayer have lost 21.7% against the industry's growth of 20.6%. BAYRY's Progress Wit ...

Logo and flags of Bayer AG are pictured outside a plant of the German pharmaceutical and chemical maker in Wuppertal, Germany. Shares of German life sciences company Bayer fell nearly 7% on Wednesday, after a U.S. court said it would review a case alleging that exposure to products of the company's Monsanto unit harmed individuals. The Washington Supreme Court this week accepted a review of litigation against the German company over the impact of polychlorinated biphenyls (PCBs) exposure at the Sky Valley E ...

Bayer Ag (BAYRY) and its wholly owned subsidiary BlueRock Therapeutics LP announced positive 24-month data from an early-stage study on experimental candidate bemdaneprocel (BRT-DA01). Bemdaneprocel, an investigational cell therapy, is being evaluated for the treatment of Parkinson's disease. exPDite is a multi-center, multi-site, open-label, non-randomized, non-controlled phase I study. Data from the phase I exPDite study at 24 months continue to show a favorable safety profile in all 12 participants in th ...

MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson joined Proactive to chat about the company's transition to commercialization from its R&D focus. He noted the commercialization of its biofertility product TerraSante, which has gained momentum in key US states. The CEO also discussed MustGrow's partnership with Bayer, which involves a commercial licensing agreement for their soil biopesticide TerraMG. Proactive: Some news today, talking in essence about what's going on within the company ...

Bayer (BAYRY) announced the submission of a supplemental new drug application (sNDA) to the FDA for darolutamide. The sNDA is seeking approval of darolutamide, in combination with androgen deprivation therapy (ADT), in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the androgen receptor with high affinity and exhibits strong antagonistic activity. It inhibits the receptor function ...

Investors might want to bet on Bayer Aktiengesellschaft (BAYRY) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...

Bayer (BAYRY) announced positive results from the expansion part of the ongoing early to mid-stage study on pipeline candidate BAY 2927088. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR) with high selectivity for mutant versus wild-type EGFR. The phase I/II SOHO-01 study evaluates the safety and pre ...

Fotofantastika Bayer (OTCPK:BAYRY) stock is down 41% since I argued for a "Strong Buy" recommendation. Indeed, Bayer may have been my worst investment recommendation over the past 18 months. That said, I apologize to readers who may have felt encouraged to trade on my writing. Today I understand that my enthusiasm for the German Life Science giant may have been too strong, underestimating the intense weight of the Monsanto litigation headwinds. However, I still feel that there is value in Bayer, especially ...